CSUH.ob: Shares of Celsius Holdings (CSUH) touched forty five cents during early trading on Monday after an
Investment Nation interview with the company's CEO Steve Haley last Thursday highlighted some important developments for the company.
Most notable of those developments, in my opinion, is the increase in distribution demand as a result of both the recent nationwide advertising campaign and the CROSSMARK signing.
While CEO Steve Haley indicated that some major distribution deals could be announced within the next month or two, my impression is that early 2010 is when distribution is going make a very significant move. As I've emphasized many times before, I thought the CROSSMARK deal was huge and the pending boom in distribution is a direct result of that deal, as well as the advertising blitz that has more retailers looking at the product.
The boom in distribution and awareness should also positively impact the stock price and the small investor wants to be in before the big moves take place. CSUH is already a big mover this year, but things could move quick if the sales numbers start lining up with the increase in distribution.
As always, do your own DD and remember, an investment in CSUH is not an investment in next week. You want to look further down the road and weigh up the potential for growth with this company.
In my opinion, any buy for the current prices is going to end up looking like a steal later on down the road.
Disclosure: VFC is long CSUH.
GNBT: Shares of Generex touched just above seventy six cents on above average volume on Monday morning after a
New York Times article over the weekend highlighted the company's Ora-Lyn insulin spray product that uses the inside lining of the cheek to deliver insulin to the bloodstream. Mannkind's insulin spray was also highlighted, although it was noted in the article that MNKD's spray utilizes the lungs to deliver the insulin, which could possibly raise more long term concerns than Ora-Lyn.
The article undoubtedly drew new interest to the company and its stock, but I still think that it might be a little bit too early to rule out another pullback in the stock price.
That being said, I still like the risk/reward of GNBT because if Ora-Lyn is approved and the company can bring additional drugs to market utilizing RapidMist, then GNBT is going to turn into a real winner of a stock, in my opinion.
My strategy is to buy on any dips with this one.
Disclosure: VFC is long GNBT.
KERX: Shares of
KERX traded up over five percent during early trading on Monday on no news and ho-hum volume.
After the recent positive news regarding Zerenex and Perifisone that spiked the stock to over three dollars, it looks like KERX has settled in a trading range of roughly $2.25-$2.75 - the lower end of that range being a good place to accumulate, in my opinion.
Any dips below $2 would have me picking up the accumulation on a larger scale. I don't foresee such a pullback based on bad news being released from the company, I just haven't ruled out another possible general market pullback to about the DOW 8500 range. A pull back like that would have some of our favorite stocks on sale once again and I think that it is worth keeping a few bucks on the sidelines just in case.
However, I'm not fully banking on a pullback so I will be accumulating shares of KERX on the dips.
Disclosure: VFC is long KERX.
